Kodiak Sciences to Present at Upcoming Conferences
Kodiak Sciences Inc. (Nasdaq: KOD) announced its participation in two virtual investor conferences. The Barclays Global Healthcare Conference is scheduled for March 10 at 8:30 a.m. PT, and the J.P. Morgan Napa Valley Forum will occur on March 31 at 8:00 a.m. PT. Both presentations will be available via live webcast on Kodiak's website, with replays accessible for a limited time after the events. Kodiak focuses on developing therapies for retinal diseases, leveraging its innovative ABC Platform™ to advance its product candidates, including KSI-301.
- None.
- None.
PALO ALTO, Calif., March 2, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that management will present at the following upcoming virtual investor conferences:
- Barclays Global Healthcare Conference on Wednesday, March 10 at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time)
- J.P. Morgan Napa Valley Forum on Wednesday, March 31 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time)
A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
View original content:http://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-upcoming-conferences-301238950.html
SOURCE Kodiak Sciences Inc.
FAQ
When will Kodiak Sciences present at the Barclays Global Healthcare Conference?
What is the significance of Kodiak's ABC Platform?
What products is Kodiak Sciences currently developing?
How can I watch Kodiak Sciences' investor presentations?
What are the dates and times for Kodiak's presentations in March 2021?
